Beta-adrenoceptor-blocking drugs: current status and the significance of partial agonist activity.
There is some evidence that partial agonism is an important property of beta-blocking drugs, and this property may be exploited to produce a new range of positive inotropic drugs. With the established beta-adrenoceptor-blocking drugs, the level of partial agonist activity is weak and the dose-response curve for this property is shallow. However, its absence appears to increase the likelihood of inducing bronchospasm and bradycardia, and drugs that lack intrinsic sympathomimetic activity appear more likely to be associated with rebound cardiac arrhythmias on cessation of treatment. The idea of a small level of hormone activity--in this case, catecholamine activity--being necessary to maintain normal cardiac and perhaps bronchial function is not new. Minimal doses of steroids are essential to maintaining the inotropic action of cardiac muscle. There is now enough accumulated evidence to suggest that a minimal degree of beta-adrenoceptor stimulation is also important for normal bronchial and cardiac function, and its absence increases the incidence of bradycardia and the risks of bronchospasm and rebound arrhythmias.
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000145:classification / Q000494:pharmacology*; D001986:Bronchial Spasm / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006321:Heart / Q000294:innervation; D006801:Humans; D009200:Myocardial Contraction / Q000187:drug effects; D011928:Raynaud Disease / Q000139:chemically induced; D013564:Sympathetic Nervous System / Q000187:drug effects
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists